Group 1 - Evergrande Property (06666) resumed trading and rose over 28% as Evergrande and liquidators plan to sell shares, with potential transactions in preliminary stages [1] - Alibaba-W (09988) increased by over 5% and Baidu Group-W (09888) rose over 8% as both companies began using internally designed chips to train their AI models, replacing some NVIDIA chips [1] - China Merchants Energy (01138) saw a rise of over 5% after announcing plans to issue A-shares to raise no more than 8 billion yuan for fleet upgrades, with increased oil production expected to boost shipping demand [1] - Kangfang Biologics (09926) increased by over 4% after presenting excellent clinical data for its drug at WCLC, highlighting its global market value [1] - NIO-SW (09866) rose over 3% as it plans to publicly issue $1 billion in shares, with Goldman Sachs expecting the funds to support the company's product strategy [1] - WanGuo Data-SW (09698) surged over 15% as AI drives data center demand, with the company fully engaging in partnerships with cloud service providers [1] - Jiajian Ankang-B (02617) rose over 32%, with its market capitalization exceeding 50 billion HKD after receiving approval for a Phase II trial of its drug [1] Group 2 - Meitu (01357) increased by over 6% after announcing a partnership with Alibaba's Tongyi Laboratory to enhance its products with advanced AI models [2] - Robotics concept stocks mostly rose, with UBTECH (09880) up over 3%, ShouCheng Holdings (00697) up over 3%, Yuejiang (02432) up over 4%, and Jizhi Jia-W (02590) up over 6%, as domestic and international catalysts for humanoid robot commercialization are expected [2] - Bilibili-W (09626) rose over 2% as it revealed its new strategy card game "Three Kingdoms: Hundred Generals Card," with institutions optimistic about the company's growth potential with AI integration [2] Group 3 - Alibaba (BABA.US) rose 8.00% after the launch of the "Gaode Street Ranking," which attracted over 40 million users on its first day, becoming the largest food ranking in China [3] - XPeng Motors (XPEV.US) increased by 2.39% after receiving a special flight permit for its "land aircraft" (X3-F) in the UAE [3] - Trip.com (TCOM.US) rose 3.21% after forming a five-year strategic partnership with Cityline, marking its first collaboration with a major ticket supplier in Hong Kong and Macau [3] - NIO (NIO.US) increased by 6.21% after completing a $1 billion equity issuance, marking its second public financing plan this year [3] - Kingsoft Cloud (KC.US) rose 5.60% as Citigroup raised its target price to $20, citing strong AI-related demand from Xiaomi [3] - NetEase (NTES.US) continued to rise by 2.98%, reaching a historical high after launching its first sci-fi shooting mobile game based on the "Destiny" IP [3] Group 4 - Adobe (ADBE.US) rose 0.11% after launching its first AI agent product suite to help customers streamline workflows across various applications [4] - Hesai (HSAI.US) increased by 0.90% as sources reported its Hong Kong IPO priced at HKD 212.8 per share, raising at least HKD 3.62 billion with oversubscription nearly 120 times [4] - Tesla (TSLA.US) rose 6.04% as the Model Y L is set to launch in the domestic market on September 19, with orders extending to November [4] - Online real estate platform Opendoor (OPEN.US) surged 79.52% after appointing Kaz Nejatian as the new CEO, with co-founder Keith Rabois returning to the board [4]

药捷安康称，替恩戈替尼靶向FGFR/VEGFR、JAK、Aurora，目前没有其他MTK抑制剂具有相同的靶向 组合。因此，在一些疾病治疗上，替恩戈替尼已经展现出独特价值。另外，该款产品正在逐步打通全球 化路径，已获国家药品监督管理局（NMPA）授予治疗胆管癌的突破性治疗品种认定及美国食品药品监 督管理局（FDA）授予治疗胆管癌及转移性去势抵抗性前列腺癌的快速通道认定，亦获FDA授予用于治 疗胆管癌的孤儿药认定，以及欧洲药品管理局（EMA）授予用于治疗胆道癌的孤儿药认定。 消息面上，药捷安康近日公布，公司核心产品替恩戈替尼（Tinengotinib，TT-00420）联合氟维司群治 疗经治失败的激素受体阳性（HR+）且人表皮生长因子受体2阴性或低表达（HER2-）的复发或转移性 乳腺癌II期临床试验，已于2025年9月10日获得了中国国家药品监督管理局的临床默示许可。 智通财经APP获悉，药捷安康-B(02617)再涨超18%，高见129.3港元再创新高，总市值一度突破500亿港 元。截至发稿，涨15%，报125港元，成交额1.51亿港元。 ...

药捷安康称，替恩戈替尼靶向FGFR/VEGFR、JAK、Aurora，目前没有其他MTK抑制剂具有相同的靶向 组合。因此，在一些疾病治疗上，替恩戈替尼已经展现出独特价值。另外，该款产品正在逐步打通全球 化路径，已获国家药品监督管理局(NMPA)授予治疗胆管癌的突破性治疗品种认定及美国食品药品监督 管理局(FDA)授予治疗胆管癌及转移性去势抵抗性前列腺癌的快速通道认定，亦获FDA授予用于治疗胆 管癌的孤儿药认定，以及欧洲药品管理局(EMA)授予用于治疗胆道癌的孤儿药认定。 消息面上，药捷安康近日公布，公司核心产品替恩戈替尼(Tinengotinib，TT-00420)联合氟维司群治疗经 治失败的激素受体阳性(HR+)且人表皮生长因子受体2阴性或低表达(HER2-)的复发或转移性乳腺癌II期 临床试验，已于2025年9月10日获得了中国国家药品监督管理局的临床默示许可。 药捷安康-B(02617)再涨超18%，高见129.3港元再创新高，总市值一度突破500亿港元。截至发稿，涨 15%，报125港元，成交额1.51亿港元。 ...

每经AI快讯，药捷安康-B(02617.HK)再涨超15%，总市值一度突破400亿港元。截至发稿，涨11.11%， 报100港元，成交额1.48亿港元。 ...

智通财经APP获悉，药捷安康-B(02617)再涨超15%，总市值一度突破400亿港元。截至发稿，涨 11.11%，报100港元，成交额1.48亿港元。 此外，上交所、深交所近日发布公告，药捷安康被调入港股通标的名单，自9月8日起生效。国元国际表 示，公司在细分行业研发领先，替恩戈替尼是全球首个且唯一进入注册临床阶段用于治疗复发或难治性 胆管癌患者的FGFR抑制剂。它也是全球首个可能同时抑制FGFR/JAK通路并针对转移性去势抵抗性前 列腺癌具有临床疗效证据的研究药物。 消息面上，药捷安康公布，核心产品替恩戈替尼(TT-00420)联合氟维司群治疗经治失败的激素受体阳性 (HR+)且人表皮生长因子受体2阴性或低表达(HER2-)的复发或转移性乳腺癌II期临床试验，已获中国国 家药品监督管理局的临床默示许可。替恩戈替尼联合氟维司群的临床治疗策略可能为乳腺癌患者的治疗 带来新的突破。 ...

药捷安康-B(02617)再涨超15%，总市值一度突破400亿港元。截至发稿，涨11.11%，报100港元，成交 额1.48亿港元。 消息面上，药捷安康公布，核心产品替恩戈替尼(TT-00420)联合氟维司群治疗经治失败的激素受体阳性 (HR+)且人表皮生长因子受体2阴性或低表达(HER2-)的复发或转移性乳腺癌II期临床试验，已获中国国 家药品监督管理局的临床默示许可。替恩戈替尼联合氟维司群的临床治疗策略可能为乳腺癌患者的治疗 带来新的突破。 此外，上交所、深交所近日发布公告，药捷安康被调入港股通标的名单，自9月8日起生效。国元国际表 示，公司在细分行业研发领先，替恩戈替尼是全球首个且唯一进入注册临床阶段用于治疗复发或难治性 胆管癌患者的FGFR抑制剂。它也是全球首个可能同时抑制FGFR/JAK通路并针对转移性去势抵抗性前 列腺癌具有临床疗效证据的研究药物。 ...

Major Events - The clinical trial for the combination treatment of Tienogtinin and Furvestrant for HR-positive/HER2-negative or low-expressing recurrent or metastatic breast cancer has been approved for Phase II [1] - Feiyang Group's subsidiary signed a strategic cooperation framework agreement with Qingdao Cultural Property Exchange Center for potential collaboration in the digitalization of cultural tourism assets [1] - Kaizhile International entered the TCG sector by reaching an operational service cooperation with the globally renowned IP Pokémon [1] - CIMC Group's BWO plans to lease two lifting living platforms, "Huaye Long" and "Huashang Long," to Hailong 16 and Hailong 17 companies [1] - Goldwind Technology intends to invest 18.92 billion in building a wind-hydrogen-ammonia integrated project in Inner Mongolia [1] Financial Data - Zhongyuan Jianye reported a contract sales of 7.28 billion for the first eight months, a year-on-year decrease of 20.0% [1] - Jianye Real Estate's total property contract sales for the first eight months reached 5.62 billion, down 5.0% year-on-year [1] - Baoshen International's cumulative operating income net for the first eight months was approximately 11.555 billion, a decline of 8.1% year-on-year [1] - China Resources Power's subsidiary power plants sold a total of 144 million megawatt-hours in the first eight months, an increase of 5.9% year-on-year [1] - Jiangshan Holdings reported a total solar power generation of approximately 218.2 thousand megawatt-hours in the first eight months, a decrease of 3.55% year-on-year [1]

Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., has received clinical approval for its core product, Tinengotinib (TT-00420), in combination with Fulvestrant for the treatment of HR+/HER2- recurrent or metastatic breast cancer that has failed previous treatments [1] Group 1: Clinical Trial Details - The clinical trial is a Phase II, open-label, multi-center study evaluating the safety, efficacy, and pharmacokinetics of Tinengotinib combined with Fulvestrant in patients with HR+/HER2- recurrent or metastatic breast cancer [1] - The trial has received clinical implicit approval from the National Medical Products Administration of China as of September 10, 2025 [1] Group 2: Early Research Results - Early clinical research results indicate that Tinengotinib as a monotherapy shows promising clinical effects in HR+/HER2- breast cancer patients who have undergone multiple treatments, including endocrine therapy, CDK4/6 inhibitors, and chemotherapy [1] - Preclinical studies suggest that the combination of Tinengotinib and Fulvestrant exhibits pharmacological synergy against endocrine-resistant breast cancer cells [1] Group 3: Potential Impact - The clinical treatment strategy involving Tinengotinib in combination with Fulvestrant may provide a new breakthrough in the treatment of breast cancer patients who have developed resistance to endocrine therapy [1]

Core Viewpoint - The company has received clinical approval for its core product, Tinengotinib, in combination with Fulvestrant, for the treatment of HR+/HER2- recurrent or metastatic breast cancer that has failed previous treatments [1] Group 1: Clinical Trial Details - The clinical trial is a Phase II, open-label, multi-center study conducted in China, evaluating the safety, efficacy, and pharmacokinetics of Tinengotinib combined with Fulvestrant in patients with HR+/HER2- breast cancer [1] - The trial received clinical implicit approval from the National Medical Products Administration of China on September 10, 2025 [1] Group 2: Early Research Findings - Early clinical research results indicate that Tinengotinib as a monotherapy shows promising clinical effects in HR+/HER2- breast cancer patients who have undergone multiple treatments, including endocrine therapy, CDK4/6 inhibitors, and chemotherapy [1] - Preclinical studies suggest that the combination of Tinengotinib and Fulvestrant exhibits pharmacological synergy against endocrine-resistant breast cancer cells [1] Group 3: Potential Impact - The clinical treatment strategy involving Tinengotinib and Fulvestrant may provide a new breakthrough in the treatment of breast cancer patients who have developed resistance to endocrine therapy [1]

智通财经APP讯，药捷安康-B(02617)公布，公司核心产品替恩戈替尼(Tinengotinib, TT-00420)联合氟维 司群治疗经治失败的激素受体阳性(HR+)且人表皮生长因子受体2阴性或低表达(HER2-)的复发或转移性 乳腺癌II期临床试验，已于2025年9月 10日获得了中国国家药品监督管理局的临床默示许可。 本试验为在中国开展的一项评价替恩戈替尼片联合氟维司群注射液用于经治失败的HR+/HER2-的复发 或转移性乳腺癌患者的安全性、疗效及药代动力学的开放标签、多中心、II期临床研究。 替恩戈替尼早期临床研究结果表明，替恩戈替尼单药在经歷过多种治疗(例如内分泌治疗、CDK4/6抑制 剂治疗和化疗)的HR+╱HER2-乳腺癌患者中，有令人鼓舞的临床效果。临床前实验结果表明，替恩戈 替尼与氟维司群的联合用药针对内分泌治疗耐药的乳腺癌细胞具有药理学协同作用。因此替恩戈替尼联 合氟维司群的临床治疗策略将可能为此类乳腺癌患者的治疗带来新的突破。 ...